Adrenocortical Carcinoma

Search Trials
Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment
Status:
Completed
Last Changed:
Jun 5, 2013
First Changed:
Sep 9, 2004
Disease(s):
Childhood Central Nervous System Germ Cell Tumor
Intervention(s):
oxaliplatin
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
Status:
Active, not recruiting
Last Changed:
May 18, 2022
First Changed:
Aug 16, 2016
Disease(s):
Adrenal Cortex Carcinoma
Intervention(s):
Cabozantinib S-malateLaboratory Biomarker AnalysisPharmacological Study
Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor
Status:
Withdrawn
Last Changed:
Sep 28, 2017
First Changed:
Jul 13, 2016
Disease(s):
Functional Pancreatic Neuroendocrine Tumor
Intervention(s):
CapecitabineTemozolomideVeliparibPharmacological StudyLaboratory Biomarker Analysis
Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer
Status:
Completed
Last Changed:
Feb 11, 2013
First Changed:
Apr 26, 2004
Disease(s):
Cancer
Intervention(s):
trastuzumabtipifarnib
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
Status:
Completed
Last Changed:
Mar 5, 2014
First Changed:
Oct 3, 2007
Disease(s):
Cancer
Intervention(s):
Fentanyl sublingual sprayPlacebo

Connect. Empower. Inspire.